CTLA-4 polymorphisms and susceptibility to Behcet's disease: a meta-analysis
1Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 126-1 Anam-dong 5 ga, Seongbuk-gu, Seoul 136-705, Korea. lyhcgh@korea.ac.kr
Molecular Biology Reports
|June 23, 2012
Summary
This meta-analysis found no link between cytotoxic T lymphocyte antigen-4 (CTLA-4) gene variations and Behcet's disease (BD) susceptibility. The study examined CTLA-4 +49 A/G, -318 C/T, and CT60 A/G polymorphisms across multiple genetic models.
Area of Science:
- Immunogenetics
- Rheumatology
- Genetic Epidemiology
Background:
- Behcet's disease (BD) is a chronic inflammatory disorder with complex etiology.
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) plays a crucial role in immune regulation.
- Genetic variations in CTLA-4 have been investigated for their potential association with autoimmune diseases.
Purpose of the Study:
- To investigate the association between specific cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to Behcet's disease (BD).
- To perform a comprehensive meta-analysis evaluating CTLA-4 +49 A/G, -318 C/T, and CT60 A/G polymorphisms in relation to BD.
Main Methods:
- A systematic meta-analysis was conducted, pooling data from 8 independent comparative studies.
- Statistical analyses included allele contrast, recessive, dominant, and additive models.
- Stratification by ethnicity was performed to assess population-specific associations.
Main Results:
- No significant association was found between the CTLA-4 +49 A/G polymorphism and BD susceptibility overall (OR = 0.780, 95% CI = 0.491-1.240, p = 0.294).
- Further analysis, including stratification by ethnicity (Turkish population), recessive, dominant, and homozygote contrast models, also revealed no association for CTLA-4 +49 A/G.
- Similarly, no statistically significant associations were identified for the CTLA-4 -318 C/T and CT60 A/G polymorphisms with Behcet's disease.
Conclusions:
- The meta-analysis concludes that the studied CTLA-4 polymorphisms (+49 A/G, -318 C/T, CT60 A/G) are not associated with an increased risk of developing Behcet's disease.
- These findings suggest that CTLA-4 gene variations may not be major genetic determinants for Behcet's disease susceptibility.
- Further research into other genetic and environmental factors is warranted to elucidate the pathogenesis of Behcet's disease.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...